paroxysmal nocturnal hemoglobinuria (PNH) | Aplastic Anemia & MDS International Foundation

paroxysmal nocturnal hemoglobinuria (PNH)

March for Marrow Texas - VIRTUAL Walk and 5K

Join together virtually with fellow patients, families, caregivers, and friends to raise awareness for

Event Date: 
Sat, 03/27/2021 to Sat, 04/03/2021
Community Event Type: 

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study

Author(s): 
Schrezenmeier H, Kulasekararaj A, Mitchell L, Sicre de Fontbrune F, Devos T, Okamoto S, Wells R, Rottinghaus ST, Liu P, Ortiz S, Lee JW, Socié G
Primary Author: 
Schrezenmeier H
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
Oct 2020

Background: Ravulizumab, the only long-acting complement C5 inhibitor for adults with

Find Out More:

Instructions:

If you are interested in learning more about your possible participation in this clinical trial, please contact Genentech directly at (888) 662-6728 (Monday - Friday, 5am - 5pm PT).

Disclaimer

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored content is highlighted only to give additional information about the trial. All trials are listed on https://clinicaltrials.gov/. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a clinical trial, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. (COMMODORE 1)

A study designed to evaluate the non-inferiority of crovalimab compared with

Find Out More:

Instructions:

If you are interested in learning more about your possible participation in this clinical trial, please contact Genentech directly at (888) 662-6728 (Monday - Friday, 5am - 5pm PT).

Disclaimer

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any clinical trial listed on this website. Pharmaceutical company sponsored content is highlighted only to give additional information about the trial. All trials are listed on https://clinicaltrials.gov/. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a clinical trial, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

David Jacobsohn, MD, ScM

Jacobsohn, David
Division Chief, Blood and Marrow Transplanation
Children's National

David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C.   Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr.

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.

Author(s): 
Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K
Primary Author: 
Peipert JD
Journal Title: 
PloS One
Original Publication Date: 
Sep 2020

Background: